Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2024-07-30 Interim / Quarterly Rep…
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Jun24 Quarterly Activities Report 4 pages 241.6KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 31 July 2024, titled 'Quarterly Activities, Cashflow Report and Operations Update' for the quarter ended 30 June 2024. It provides detailed operational highlights, cash flow information, clinical trial updates, regulatory status, capital requirements, payments to directors, and use of funds. The content includes substantive financial data such as cash reserves, net cash generated, loan drawdowns, R&D tax incentives, and expenditure breakdowns. The document is comprehensive and covers a period shorter than a full fiscal year (a quarter). It is not merely an announcement of a report but contains actual financial and operational data. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2024
2024-07-30 English
Live Investor Webinar 19 pages 3.7MB
Investor Presentation Classification · 95% confidence The document is a detailed investor presentation dated 25 July 2024 by InhaleRx Ltd. It includes extensive information about the company's strategy, management team, product development, market opportunity, and clinical trials. The text mentions a live investor webinar and that a copy of the presentation is attached. The content is focused on providing investors with a comprehensive overview of the company's business, pipeline, and market positioning, typical of an investor presentation. There is no indication that this is a regulatory filing, earnings release, or annual/interim report. The length (15,000 characters) and detailed content confirm it is the presentation itself, not just an announcement of a report. Therefore, the appropriate classification is Investor Presentation (IP).
2024-07-24 English
IRX616a IND Application Outcome 2 pages 180.0KB
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the FDA placing a temporary suspension (clinical hold) on an Investigational New Drug (IND) application for a phase 1 clinical trial. It discusses regulatory actions, clinical trial status, and company plans to respond. There are no financial statements, earnings data, or detailed financial analysis. The document is a regulatory update about a clinical trial status and FDA interaction, not a financial report or meeting material. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-07-04 English
Final Clinical Study Report Received, Phase 1 IRX-211 2 pages 179.6KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that InhaleRx Ltd has received the final Clinical Study Report (CSR) for their Phase 1 clinical trial of IRX-211. It summarizes the trial results, safety, and plans for Phase 2, but does not contain the actual clinical study report or detailed data. The document length is under 5,000 characters and it is an announcement of receipt of a report rather than the report itself. There are no financial statements or regulatory filings typical of financial reports. Therefore, this fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about clinical trial progress and report receipt, not a financial or governance report.
2024-07-02 English
Change of Director's Interest Notice - Sean Williams 2 pages 307.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number and class of securities before and after the change, nature of the interest, and dates. This is a clear report of personal share transactions by a company director. The document length is 4173 characters, which is consistent with a detailed director's dealing notice. There is no indication that this is an announcement of a report or a certification. Therefore, the document fits the definition of Director's Dealing (DIRS).
2024-06-05 English
Notification regarding unquoted securities - IRX 7 pages 21.5KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted options under an employee incentive scheme by Inhalerx Limited. It includes specifics such as the number of securities issued, exercise price, expiry date, and references to ASX listing rules and shareholder approval. The content focuses on the issuance of new securities and changes in capital structure rather than financial results, management changes, or regulatory compliance filings. This matches the definition of a Share Issue/Capital Change announcement, which covers new share issues, stock splits, or other capital changes. The document is about notifying the market of a new class of unquoted options issued, fitting the Share Issue/Capital Change category (SHA). The document length (6890 characters) and detailed content confirm it is the announcement itself, not just a notice of report publication or a certification. Therefore, the correct classification is SHA with high confidence.
2024-06-02 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.